Design, Synthesis, and Anti-tumor Activity of Novel 2-Aryl Benzimidazole Compounds


Цитировать

Полный текст

Аннотация

Background: Combretastatin A-4 (CA-4) is a natural product isolated from the bark of the South African bush willow tree Combretum caffrum, which exerts tubulin inhibition, but its clinical application is limited due to poor stability and water solubility. 2-aryl benzimidazoles are excellent pharmacological skeletons with many activities, especially in tumor inhibition, and better pharmacokinetic properties. Several scaffold CA-4 analogs have been synthesized to date possessing antitumor activities.

Objective: The benzimidazole was applied as the core moiety to replace the B ring and unstable linkage of CA-4, and the 5-aryl acetenyl group was introduced to improve the antitumor activity. MCF-7, A549, Caco-2, Siha, and Eca-109 tumor cell lines were used to study inhibition by these agents in vitro.

Methods: The benzimidazole structure was constructed from the oxidation of o-nitroaniline and aldehyde and the following schemes, and the structural characterization was carried out. The antitumor effects were evaluated in vitro through MTT assay, cell cycle arrest, and apoptosis assay. Molecular docking with tubulin (Protein ID: 1SA0) was analyzed for the structure-activity relationship.

Results: Among these derivatives, 4a-4h series (with 6-methoxy group) compounds inhibited the tumor cell lines much stronger than the CA-4 and cisplatin, especially compound 4f showed prominently inhibitory activity in Siha cell with IC50 value as 0.61 µmol/L. The further assay showed that the cell cycle was arrested at the G0/G1 phase as well verified in apoptosis assay. Molecular docking indicated that 4f had stronger affinity energy and hydrogen bond than CA-4.

Conclusion: The compound 4f has the potency to be used as an anti-tubulin agent and the 2-trimethoxyphenyl benzimidazole skeleton deserves further study as an antitumor structure.

Ключевые слова

Об авторах

Haimiti Xiaohelaiti

Department of Medicinal and Organic Chemistry, College of Pharmacy, Xinjiang Medical University

Email: info@benthamscience.net

Wenping Wu

Department of Medicinal and Organic Chemistry, College of Pharmacy, Xinjiang Medical University

Email: info@benthamscience.net

Yiting Gao

Department of Medicinal and Organic Chemistry, College of Pharmacy, Xinjiang Medical University

Email: info@benthamscience.net

Sisi Li

Department of Medicinal and Organic Chemistry, College of Pharmacy, Xinjiang Medical University

Email: info@benthamscience.net

Cheng Ma

Department of Medicinal and Organic Chemistry, College of Pharmacy, Xinjiang Medical University

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33. doi: 10.3322/caac.21708 PMID: 35020204
  2. Chung, W.P.; Huang, W.L.; Lee, C.H.; Hsu, H.P.; Huang, W.L.; Liu, Y.Y.; Su, W.C. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations. Am. J. Cancer Res., 2022, 12(7), 3067-3082. doi: 10.1159/000520793 PMID: 35968355
  3. Jiang, Q.; Huang, J.; Zhang, B.; Li, X.; Chen, X.; Cui, B.; Li, S.; Guo, G. Efficacy and safety of anti-PD1/PDL1 in advanced biliary tract cancer: A systematic review and meta-analysis. Front. Immunol., 2022, 13801909 doi: 10.3389/fimmu.2022.801909 PMID: 35309350
  4. Bhogal, T.; Cameron, D.; Palmieri, C. Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. Breast, 2022, 63, 85-100. doi: 10.1016/j.breast.2022.03.013 PMID: 35344688
  5. Du, R.; Wang, X.; Ma, L.; Larcher, L.M.; Tang, H.; Zhou, H.; Chen, C.; Wang, T. Adverse reactions of targeted therapy in cancer patients: A retrospective study of hospital medical data in China. BMC Cancer, 2021, 21(1), 206-219. doi: 10.1186/s12885-021-07946-x PMID: 33639888
  6. Liu, Y.; Xu, Y.; Cheng, X.; Lin, Y.; Jiang, S.; Yu, H.; Zhang, Z.; Lu, L.; Zhang, X. Research trends and most influential clinical studies on Anti-PD1/PDL1 immunotherapy for cancers: A bibliometric analysis. Front. Immunol., 2022, 13862084 doi: 10.3389/fimmu.2022.862084 PMID: 35493449
  7. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; Norris, A.; Sanseau, P.; Cavalla, D.; Pirmohamed, M. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov., 2019, 18(1), 41-58. doi: 10.1038/nrd.2018.168 PMID: 30310233
  8. Shuai, W.; Wang, G.; Zhang, Y.; Bu, F.; Zhang, S.; Miller, D.D.; Li, W.; Ouyang, L.; Wang, Y. Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy. J. Med. Chem., 2021, 64(12), 7963-7990. doi: 10.1021/acs.jmedchem.1c00100 PMID: 34101463
  9. Turner, N.; Dent, R.A.; O'Shaughnessy, J.; Kim, S.B.; Isakoff, S.J.; Barrios, C.; Saji, S.; Bondarenko, I.; Nowecki, Z.; Lian, Q.; Reilly, S.J.; Hinton, H.; Wongchenko, M.J.; Kovic, B.; Mani, A.; Oliveira, M. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: Primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res. Treat., 2022, 191(3), 565-576. doi: 10.1007/s10549-021-06450-x PMID: 34860318
  10. Ren, S.; Chen, J.; Xu, X.; Jiang, T.; Cheng, Y.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Hu, S.; Guo, R.; Shi, J.; Wang, Z.; Cao, P.; Wang, D.; Fang, J.; Luo, H.; Geng, Y.; Xing, C.; Lv, D.; Zhang, Y.; Yu, J.; Cang, S.; Yang, Z.; Shi, W.; Zou, J.; Zhou, C. CameL-sq Study Group. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial. J. Thorac. Oncol., 2022, 17(4), 544-557. doi: 10.1016/j.jtho.2021.11.018 PMID: 34923163
  11. Paidakula, S.; Nerella, S.; Kankala, S.; Kankala, R.K. Recent trends in tubulin-binding combretastatin A-4 analogs for anticancer drug development. Curr. Med. Chem., 2022, 29(21), 3748-3773. doi: 10.2174/0929867328666211202101641 PMID: 34856892
  12. Pettit, G.R.; Minardi, M.D.; Hogan, F.; Price, P.M. An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins. J. Nat. Prod., 2010, 73(3), 399-403. doi: 10.1021/np9004486 PMID: 20028026
  13. Nik, M.E.; Momtazi-Borojeni, A.A.; Zamani, P.; Navashenaq, J.G.; Iranshahi, M.; Jaafari, M.R.; Malaekeh-Nikouei, B. Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment. J. Cell. Physiol., 2019, 234(9), 14721-14733. doi: 10.1002/jcp.28230 PMID: 30697744
  14. Baytas, S.N. Recent advances in combretastatin A-4 inspired inhibitors of tubulin polymerization: An update. Curr. Med. Chem., 2022, 29(20), 3557-3585. doi: 10.2174/1871526522666220105114437 PMID: 34986762
  15. Karatoprak, G. Ş.; Küpeli Akkol, E.; Genç, Y.; Bardakcı, H.; Yücel, Ç.; Sobarzo-Sánchez, E. Combretastatins: An overview of structure, probable mechanisms of action and potential applications. Molecules, 2020, 25(11), 2560. doi: 10.3390/molecules25112560 PMID: 32486408
  16. Reipsch, F.; Biersack, B.; Lucas, H.; Schobert, R.; Mueller, T. Imidazole analogs of vascular-disrupting Combretastatin A-4 with pleiotropic efficacy against resistant colorectal cancer models. Int. J. Mol. Sci., 2021, 22(23), 13082. doi: 10.3390/ijms222313082
  17. Liu, X.; Pang, X.J.; Liu, Y.; Liu, W.B.; Li, Y.R.; Yu, G.X.; Zhang, Y.B.; Song, J.; Zhang, S.Y. Discovery of novel diarylamide N-Containing heterocyclic derivatives as new tubulin polymerization inhibitors with anti-cancer activity. Molecules, 2021, 26(13), 4047. doi: 10.3390/molecules26134047
  18. Hamze, A.; Alami, M.; Provot, O. Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents. Eur. J. Med. Chem., 2020, 190112110 doi: 10.1016/j.ejmech.2020.112110 PMID: 32061961
  19. Romagnoli, R.; Oliva, P.; Salvador, M.K.; Camacho, M.E.; Padroni, C.; Brancale, A.; Ferla, S.; Hamel, E.; Ronca, R.; Grillo, E.; Bortolozzi, R.; Rruga, F.; Mariotto, E.; Viola, G. Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors. Eur. J. Med. Chem., 2019, 181111577 doi: 10.1016/j.ejmech.2019.111577 PMID: 31400707
  20. Yang, J.H.; Yu, Y.M.; Li, Y.; Yan, W.; Ye, H.Y.; Niu, L.; Tang, M.H.; Wang, Z.F.; Yang, Z.H.; Pei, H.Y.; Wei, H.C.; Zhao, M.; Wen, J.L.; Yang, L.Y.; Ouyang, L.; Wei, Y.Q.; Chen, Q.; Li, W.M.; Chen, L.J. Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect. Sci. Adv., 2021, 7(21)eabg4168 doi: 10.1126/sciadv.abg4168
  21. Yang, X.; Cheng, B.; Xiao, Y.; Xue, M.; Liu, T.; Cao, H.; Chen, J. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. Eur. J. Med. Chem., 2021, 213113058 doi: 10.1016/j.ejmech.2020.113058 PMID: 33280898
  22. Wu, K.; Peng, X.; Chen, M.; Li, Y.; Tang, G.; Peng, J.; Peng, Y.; Cao, X. Recent progress of research on anti-tumor agents using benzimidazole as the structure unit. Chem. Biol. Drug Des., 2022, 99(5), 736-757. doi: 10.1111/cbdd.14022 PMID: 35064629
  23. Vasava, M.S.; Bhoi, M.N.; Rathwa, S.K.; Jethava, D.J.; Acharya, P.T.; Patel, D.B.; Patel, H.D. Benzimidazole: A milestone in the field of medicinal chemistry. Mini Rev. Med. Chem., 2020, 20(7), 532-565. doi: 10.2174/1389557519666191122125453 PMID: 31755386
  24. Fan, Y.; Luo, Y.; Ma, C. Synthesis and cytotoxic evaluation of combretastatin A-4 analogues of benzobfurans. Monatsh. Chem., 2017, 148(10), 1823-1832. doi: 10.1007/s00706-017-2001-1
  25. Gao, Y.T.; Ma, C.; Xiaohelaiti, H.M.T. BF12, a novel benzofuran, exhibits anti-tumor activity by inhibiting microtubules and thePI3K/Akt/mTOR signaling pathway in human cervical cancer cells. Chem. Biodivers., 2020, 17(3)e1900622 doi: 10.1002/cbdv.201900622
  26. Feng, L.S.; Su, W.Q.; Cheng, J.B.; Xiao, T.; Li, H.Z.; Chen, D.A.; Zhang, Z.L. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure–activity relationship, and mechanisms of action (2019–2021). Arch. Pharm., 2022, 355(6)2200051 doi: 10.1002/ardp.202200051 PMID: 35385159
  27. Gilfillan, L.; Blair, A.; Morris, B.J.; Pratt, J.A.; Schweiger, L.; Pimlott, S.; Sutherland, A. Synthesis and biological evaluation of novel 2,3-dihydro-1H-1,5-benzodiazepin-2-ones; potential imaging agents of the metabotropic glutamate 2 receptor. MedChemComm, 2013, 4(7), 1118-1123. doi: 10.1039/C3MD00110E
  28. Won, D.I.; Lee, J.S.; Ji, J.M.; Jung, W.J.; Son, H.J.; Pac, C.; Kang, S.O. Highly robust hybrid photocatalyst for carbon dioxide reduction: Tuning and optimization of catalytic activities of Dye/TiO 2/Re(I) organic–inorganic ternary systems. J. Am. Chem. Soc., 2015, 137(42), 13679-13690. doi: 10.1021/jacs.5b08890 PMID: 26456369
  29. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791. doi: 10.1002/jcc.21256 PMID: 19399780
  30. PyMOL Molecular Graphics System, version 1.7.4; Schrodinger: LLC, New York, 2015. Available from: http://www.pymol.org

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2023